Drugs / B11-FC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06580236 | Aug 2024 → Mar 2025 overdue | botulism | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B11-FC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06580236 ↗ |
| Modality | Monoclonal antibody | “The therapeutic dose is calculated based on the activity of monoclonal antibodies included in the drug.” NCT06580236 ↗ |